The nucleus of ChemoCentryx's research is molecular cell secretions. The drug developer focuses on orally administered drugs targeting the body's chemokine system, a molecular network that regulates inflammatory and immune responses. Its lead candidate in clinical development is Traficet-EN, a potential treatment for Crohn's disease. ChemoCentryx is researching other compounds that could treat type 2 diabetes and a form of brain cancer. Its R&D activities for Traficet-EN are being done in collaboration with GlaxoSmithKline, which is providing research funding and clinical trials in return for the right to license Traficet-EN. ChemoCentryx was founded in 1997 and has filed to go public.